20170320 2016 Resultats annuels EN
Year: 2017
First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
20170313 FPI Kelly study EN
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Faleh Husseini, et al. Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the article Publication TG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.
Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers
20170213 ISI-JX FPI EN final
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
Gilda G. Hillman, et al. Journal for ImmunoTherapy of Cancer, January 2017 – Download the article Publication
Transgene Announces Financial Calendar for 2017
20170105 financial calendar EN